

Technology Advisory Committee C Interests Register

Topic [ID3943]

Publication Date: TBC

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Comments
Dr Andrea Kuhl	Clinical Expert	Direct financial	Dr Kuhl has received conference support and honoraria from Gilead/Kite and has been on their advisory board. Dr Kuhl has attended a Roche advisory board. Dr Kuhl has attended a BMS advisory board.	03.03.2023	It was agreed that Dr Andrea Kuhl declaration would not prevent her from providing expert advice to the committee.
Dr Cathy Burton	Clinical Expert	Direct financial	Dr Burton has received funding from Roche, BMS and Kite for advisory boards, honoraria for talks and support to attend conferences. Dr Cathy Burton is a Trustee of Lymphoma Action.	03.03.2023	It was agreed that Dr Cathy Burton's declaration would not prevent her from providing expert advice to the committee.
Elizabeth Thurgar	TAC C Committee Member	Financial Interest	Elizabeth Thurgar has just kicked off a project where she will be reviewing a global model for BREXU-CEL (Kite) in mantle cell lymphoma (MCL). MCL is a form of NHL although distinct from DLBCL	18.10.2023	It was agreed that Elizabeth Thurgar's declaration would not prevent her from participating in discussions on this appraisal.

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Comments
Dr Kate Ren	TAC C Committee Member	Financial Interest	Dr Kate Ren provided statistical methodology consultancy service for a possible comparator company Pfizer for an unrelated treatment in an unrelated disease area (Tofacitinib for Moderate-to-Severe Ulcerative Colitis).	18.10.2023	It was agreed that Dr Kate Ren's declaration would not prevent her from participating in discussions on this appraisal.
Dr Richard Nicholas	TAC C Committee Member	Financial Interest	Dr Richard Nicholas has attended paid advisory boards for an unrelated condition - multiple sclerosis.	31.10.2023	It was agreed that Dr Richard Nicholas' declaration would not prevent him from participating in discussions on this appraisal.
Satish Venkateshan	TAC C Committee Member	Financial Interest	Regeneron is developing Odronextamab CD20xCD3 bispecific antibody and has filed for EMA approval to treat adult patients with relapsed/refractory (R/R) follicular lymphoma (FL) or R/R diffuse large B-cell lymphoma (DLBCL), who have progressed after at least two prior systemic therapies. Regeneron also has other pipeline assets in development in haematology. Satish Venkateshan works for Regeneron, pharmaceuticals/biotech company. Satish also own shares in the company and has stock options	18.10.2023	It was agreed that Satish Venkateshan's declaration would prevent him from participating in discussions on this appraisal.

DRAFT